

Product Information Sheet for NR-10178

Tamiami Virus, W-10777

Catalog No. NR-10178

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Charles H. Calisher, Professor, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine & Biomedical Sciences, Colorado State University, Fort Collins, Colorado

Manufacturer:

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:

Virus Classification: Arenaviridae, Arenavirus

<u>Species</u>: Tamiami virus (TAMV) <u>Type Strain/Isolate</u>: W-10777

Original Source: Tamiami virus (TAMV), W-10777 was isolated by John Davie at the National Communicable Disease Center from heart tissue of an adult male hispid cotton rat (*Sigmodon hispidus*) captured January 5, 1965 in a box trap in southern Florida.^{1,2}

<u>Comment</u>: Both small (S) and large (L) RNA segments of TAMV, W-10777 have been sequenced (GenBank: AF485263 and AY924393, respectively).^{3,4}

TAMV is a new world arenavirus which, although highly antigenically related to Junin virus and lethal to mice, has low pathogenic potential for humans. TAMV shares a similar genomic organization with all other arenaviruses, displaying a bipartite, ambisense, single-stranded RNA genome.

Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from African green monkey kidney cells [VERO C1008 (E6); ATCC[®] CRL-1586™] infected with TAMV, W-10777.

<u>Note</u>: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-10178 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -70°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: VERO C1008 (E6) cells (ATCC® CRL-1586™)
 Growth Medium: Minimum Essential Medium supplemented with 2% irradiated fetal bovine serum, or equivalent
 Infection: Cells should be 80-90% confluent (not 100% confluent)

Incubation: 12 to 15 days at 37°C and 5% CO₂

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Tamiami Virus, W-10777, NR-10178."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Calisher, C. H., et al. "Tamiami Virus, a New Member of

Biodefense and Emerging Infections Research Resources Repository

www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Product Information Sheet for NR-10178

- the Tacaribe Group." <u>Am. J. Trop. Med. Hyg.</u> 19 (1970): 520-526. PubMed: 5446318.
- "No. 242, Tamiami (TAM) Strain: W-10777." <u>Am. J. Trop. Med. Hyg.</u> 19 (1970): Suppl. 1157-1158. PubMed: 4395318.
- Archer, A. M. and R. Rico-Hesse. "High Genetic Divergence and Recombination in Arenaviruses from the Americas." <u>Virology</u> 304 (2002): 274-281. PubMed: 12504568. GenBank: AF485263.
- Cajimat, M. N. B., et al. "Principal Host Relationships and Evolutionary History of the North American Arenaviruses." <u>Virology</u> 367 (2007): 235-243. PubMed: 17624390. GenBank: AY924393.
- Jennings, W. L. et al. "Tamiami Virus in the Tampa Bay Area." <u>Am. J. Trop. Med. Hyg.</u> 19 (1970): 527-536. PubMed: 5446319.
- Winn, W. C. Jr. and F. A. Murphy. "Tamiami Virus Infection in Mice and Cotton Rats." <u>Bull. World Health</u> Organ. 52 (1975): 501-506. PubMed: 182400.
- Charrel, R. N., X. de Lamballerie and S. Emonet. "Phylogeny of the Genus Arenavirus." <u>Curr. Opin.</u> <u>Microbiol.</u> 11 (2008): 362-368. PubMed: 18602020.
- Bowen, M. D., C. J. Peters, and S. T. Nichol. "The Phylogeny of New World (Tacaribe Complex) Arenaviruses." <u>Virology</u> 219 (1996): 285-290. PubMed: 8623541.

ATCC[®] is a trademark of the American Type Culture Collection.

Biodefense and Emerging Infections Research Resources Repository www.beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

NR-10178_28FEB2011

E-mail: contact@beiresources.org